Marion Dorsch

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Participation of Rip2 in lipopolysaccharide signaling is independent of its kinase activity
    Chafen Lu
    Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts 02139, USA
    J Biol Chem 280:16278-83. 2005
  2. ncbi Nucleotide binding to CARD12 and its role in CARD12-mediated caspase-1 activation
    Chafen Lu
    Millennium Pharmaceuticals, Inc, 35 Landsdowne Street, Cambridge, MA 02139, USA
    Biochem Biophys Res Commun 331:1114-9. 2005
  3. ncbi Validating cancer drug targets
    John D Benson
    Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA
    Nature 441:451-6. 2006
  4. ncbi Identification of a regulatory autophosphorylation site in the serine-threonine kinase RIP2
    Marion Dorsch
    Millennium Pharmaceuticals, Inc, 35 Landsdowne St, Cambridge, MA 02130, USA
    Cell Signal 18:2223-9. 2006
  5. ncbi Regulation of IRAK-4 kinase activity via autophosphorylation within its activation loop
    Hong Cheng
    Department of Inflammation, Millennium Pharmaceuticals, Inc, Cambridge, MA 02139, USA
    Biochem Biophys Res Commun 352:609-16. 2007
  6. ncbi The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells
    Zainab Jagani
    Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA
    Cancer Res 70:5528-38. 2010
  7. ncbi Mice deficient in PKC theta demonstrate impaired in vivo T cell activation and protection from T cell-mediated inflammatory diseases
    Karen Anderson
    Inflammation Department, Millennium Pharmaceuticals Inc, 40 Landsdowne St, Cambridge, MA 02139, USA
    Autoimmunity 39:469-78. 2006
  8. ncbi 1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity
    Karen Miller-Moslin
    Department of Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 01239, USA
    J Med Chem 52:3954-68. 2009
  9. ncbi Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma
    Silvia Buonamici
    Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
    Sci Transl Med 2:51ra70. 2010
  10. ncbi PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers
    Susan Wee
    Novartis Institutes for BioMedical Research, Cambridge, MA, USA
    Cancer Res 69:4286-93. 2009

Collaborators

Detail Information

Publications14

  1. ncbi Participation of Rip2 in lipopolysaccharide signaling is independent of its kinase activity
    Chafen Lu
    Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts 02139, USA
    J Biol Chem 280:16278-83. 2005
    ..These results demonstrate that Rip2-mediated LPS signaling is independent of its kinase activity. Our findings strongly suggest that Rip2 functions as an adaptor molecule in transducing signals from immune receptors...
  2. ncbi Nucleotide binding to CARD12 and its role in CARD12-mediated caspase-1 activation
    Chafen Lu
    Millennium Pharmaceuticals, Inc, 35 Landsdowne Street, Cambridge, MA 02139, USA
    Biochem Biophys Res Commun 331:1114-9. 2005
    ..Thus, CARD12 function is dependent on the nucleotide-binding site. Our data provide insights into the molecular mechanisms of CARD12-mediated caspase-1 activation...
  3. ncbi Validating cancer drug targets
    John D Benson
    Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA
    Nature 441:451-6. 2006
    ..Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established...
  4. ncbi Identification of a regulatory autophosphorylation site in the serine-threonine kinase RIP2
    Marion Dorsch
    Millennium Pharmaceuticals, Inc, 35 Landsdowne St, Cambridge, MA 02130, USA
    Cell Signal 18:2223-9. 2006
    ..In summary, our results indicate that S176 is a regulatory autophosphorylation site for RIP2 and that S176 phosphorylation can be used to monitor the activation state of RIP2...
  5. ncbi Regulation of IRAK-4 kinase activity via autophosphorylation within its activation loop
    Hong Cheng
    Department of Inflammation, Millennium Pharmaceuticals, Inc, Cambridge, MA 02139, USA
    Biochem Biophys Res Commun 352:609-16. 2007
    ..The present data indicate that the kinase activity of IRAK-4 is dependent on the autophosphorylations at T342, T345, and S346 in the activation loop...
  6. ncbi The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells
    Zainab Jagani
    Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA
    Cancer Res 70:5528-38. 2010
    ..Therefore, these studies not only highlight Bmi-1 as a cancer-dependent factor in multiple myeloma, but also elucidate a novel antiapoptotic mechanism for Bmi-1 function involving the suppression of Bim...
  7. ncbi Mice deficient in PKC theta demonstrate impaired in vivo T cell activation and protection from T cell-mediated inflammatory diseases
    Karen Anderson
    Inflammation Department, Millennium Pharmaceuticals Inc, 40 Landsdowne St, Cambridge, MA 02139, USA
    Autoimmunity 39:469-78. 2006
    ..A fundamental role for PKC theta in T cell activation and in the development of T cell-mediated inflammatory diseases is indicated by these results...
  8. ncbi 1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity
    Karen Miller-Moslin
    Department of Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 01239, USA
    J Med Chem 52:3954-68. 2009
    ..This compound displayed a good pharmacokinetic profile and also afforded tumor regression in a genetic mouse model of medulloblastoma...
  9. ncbi Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma
    Silvia Buonamici
    Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
    Sci Transl Med 2:51ra70. 2010
    ..Our findings may be useful in informing treatment strategies for medulloblastoma...
  10. ncbi PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers
    Susan Wee
    Novartis Institutes for BioMedical Research, Cambridge, MA, USA
    Cancer Res 69:4286-93. 2009
    ..Our study provides molecular insights that help explain the heterogeneous response of KRAS mutant cancers to MEK pathway inhibition and presents a strong rationale for the clinical testing of combination MEK and PI3K targeted therapies...
  11. ncbi PK1/EG-VEGF induces monocyte differentiation and activation
    Marion Dorsch
    Millennium Pharmaceuticals Inc, 35 Landsdowne St, Cambridge, MA 02139, USA
    J Leukoc Biol 78:426-34. 2005
    ..PK1 induces a distinct monocyte-derived cell population, which is primed for release of proinflammatory cytokines that favor a T helper cell type 1 response...
  12. ncbi Hedgehog pathway activation in chronic myeloid leukemia
    Zainab Jagani
    Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, MA, USA
    Cell Cycle 9:3449-56. 2010
    ....
  13. ncbi Distinct effects of the soluble versus membrane-bound forms of the notch ligand delta-4 on human CD34+CD38low cell expansion and differentiation
    Medhi Lahmar
    U790 INSERM, Institut Gustave Roussy, University Paris XI, PR1, 94800 Villejuif, France
    Stem Cells 26:621-9. 2008
    ..Altogether, these results suggest that part of solD4 activity did not rely upon canonical Notch pathway...
  14. ncbi Ikkepsilon regulates viral-induced interferon regulatory factor-3 activation via a redox-sensitive pathway
    Hemalatha Indukuri
    Department of Pediatrics, University of Texas Medical Branch, Galveston, TX 77555-0366, USA
    Virology 353:155-65. 2006
    ....